TP53 and diffuse large B-cell lymphoma: Compared with R-CHOP, zanubrutinib plus R-CHOP effectively increased the CR rate of DE-DLBCL and showed a tendency to delay disease progression, especially in DE-DLBCL with Ki67 index >75% or p53 expression >50%.